Daniel L.  Alkon net worth and biography

Daniel Alkon Biography and Net Worth

Insider of Synaptogenix
Dr. Alkon has served as President and Chief Scientific Officer of Synaptogenix since September 2016 and the Founding Chief Scientific Officer since 2012 . A leader in the field, Dr. Alkon comes to Synaptogenix after 30 years directing programs on the molecular basis of associative memory at the National Neurologic Institute of NIH, and another 15 years as the Founding Scientific Director of the Blanchette Rockefeller. Neuroscience Institute where he and his team developed neurorestorative therapeutics for degenerative disorders of the central nervous system. He also served as the Toyota Chair of Neurodegenerative Diseases and Professor of Neurology at West Virginia University and Research Professor of Biophysics at Johns Hopkins University before joining Synaptogenix.

An internationally recognized pioneer in research on brain-based neural networks, the molecular basis of memory, and degenerative brain disorders, he has authored hundreds of scientific articles as well as several books, including Memory Traces in the Brain by Cambridge University Press, and the popular book Memory’s Voice by Harper Collins.

Dr. Alkon received his B.A. from the University of Pennsylvania, and his M.D. at Cornell University, after which he interned at the Mt Sinai Hospital in New York.

What is Daniel L. Alkon's net worth?

The estimated net worth of Daniel L. Alkon is at least $3,651.97 as of December 16th, 2022. Dr. Alkon owns 1,421 shares of Synaptogenix stock worth more than $3,652 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Alkon may own. Additionally, Dr. Alkon receives a salary of $375,000.00 as Insider at Synaptogenix. Learn More about Daniel L. Alkon's net worth.

How old is Daniel L. Alkon?

Dr. Alkon is currently 82 years old. There are 2 older executives and no younger executives at Synaptogenix. Learn More on Daniel L. Alkon's age.

What is Daniel L. Alkon's salary?

As the Insider of Synaptogenix, Inc., Dr. Alkon earns $375,000.00 per year. The highest earning executive at Synaptogenix is Mr. Robert Weinstein, CFO, Executive VP, Treasurer & Secretary, who commands a salary of $568,920.00 per year. Learn More on Daniel L. Alkon's salary.

How do I contact Daniel L. Alkon?

The corporate mailing address for Dr. Alkon and other Synaptogenix executives is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. Synaptogenix can also be reached via phone at 973-242-0005 and via email at [email protected]. Learn More on Daniel L. Alkon's contact information.

Has Daniel L. Alkon been buying or selling shares of Synaptogenix?

Daniel L. Alkon has not been actively trading shares of Synaptogenix during the last ninety days. Most recently, Daniel L. Alkon sold 787 shares of the business's stock in a transaction on Friday, December 16th. The shares were sold at an average price of $29.25, for a transaction totalling $23,019.75. Following the completion of the sale, the insider now directly owns 1,421 shares of the company's stock, valued at $41,564.25. Learn More on Daniel L. Alkon's trading history.

Daniel L. Alkon Insider Trading History at Synaptogenix

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2022Sell787$29.25$23,019.751,421View SEC Filing Icon  
6/14/2021Buy400$206.50$82,600.00459View SEC Filing Icon  
See Full Table

Daniel L. Alkon Buying and Selling Activity at Synaptogenix

This chart shows Daniel L Alkon's buying and selling at Synaptogenix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Synaptogenix Company Overview

Synaptogenix logo
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.
Read More

Today's Range

Now: $2.57
Low: $2.56
High: $2.60

50 Day Range

MA: $3.02
Low: $2.40
High: $3.60

2 Week Range

Now: $2.57
Low: $2.32
High: $8.78

Volume

3,256 shs

Average Volume

37,282 shs

Market Capitalization

$3.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19